This session will address currently available treatment options for patients with non-cirrhotic MASH. Recent publications on real world use of resmetirom include high observed rates of prescription coverage but frequent AE s. Furthermore, early data on the use of resmetirom for 3 years in non-cirrhotic MASH and 2 years in patients with MASH cirrhosis are becoming available. Lastly, weekly semaglutide injections were approved by the FDA in September 2025 for non-cirrhotic MASH patients. In late 2025, the AASLD will publish an updated guidance on MASLD management that will be presented at the November Annual meeting. Therefore, there is an urgent need for members to become aware of the latest evidence based recommendations on what agents to select and how to optimally treat individual patients. In addition as the approved agents are used alone or in combination with other treatment strategies participants need to familiarize themselves with future options in this rapidly changing therapeutic landscape.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Address:
- 1001 North Fairfax
Top 6 courses
-
-
-
-
-
-
PSVD-NCPF Nomenclature
0.5 Credits
Specialties served/covered
- Adolescent Medicine
- Endocrinology, Diabetes & Metabolism
- Family Medicine
- Gastroenterology
- Gastrointestinal Surgery
- General Internal Medicine
- General Pediatrics
- Health Equity & Inclusion
- Hematology
- Hospice & Palliative Medicine
- Interventional Radiology
- Medical Oncology
- Patient Safety & Quality Improvement
- Pediatric Gastroenterology
- Pediatric Transplant Hepatology
- Radiation Oncology
- Surgical Oncology
- Transplant Hepatology
- Cross-Specialty
- GI & Liver
- Internal Medicine
- Medical Subspecialties
- Oncology & Hematology
- Pain & Palliative
- Pediatrics
- Primary care
- Radiology
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Blended / Other
- Credit · Up to 1 credit
- MOC · Up to 1 point
-
ReleasedDec 16, 2025
-
Last day to claim creditDec 17, 2026 2 months left
-
Catalyst Medical Education, LLC +1 A New Era in MASH: How Disease-Specific Therapies Are Changing the Game and Best Practices for Clinical Integration
-
Obesity Medicine Association Obesity Medicine 2025 – Evidence-Based Management of MASLD and MASH in Patients with Obesity (Recorded)
-
CME Outfitters, LLC GLP-1s Got That Rizz: The Future of MASH & Metabolic Syndrome Care
-
American Association for the Study of Liver Diseases Semaglutide Therapy for Metabolic Dysfunction-Associated Steatohepatitis: November 2025 updates
-
American Association for the Study of Liver Diseases SIG Greatest Hits: TLM 2025
-
American Association for the Study of Liver Diseases Guideline Update: Adult Liver Transplantation: Candidate Evaluation
